Concepedia

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Lieneke F.M. Ariëns, Jorien van der Schaft, Daphne S. Bakker, Deepak M.W. Balak, Margreet L. E. Romeijn, T. Kouwenhoven, Marijke Kamsteeg, Barbara Giovannone, Julia Drylewicz, Cynthia C. A. van Amerongen,

Allergy · 2019 · 146 citations · 15 references

DOIFull text

Open access

Abstract

Treatment with dupilumab significantly improved disease severity and decreased severity-related serum biomarkers in patients with very difficult-to-treat AD in a daily practice setting.

References

15

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Mario Castro, Jonathan Corren, Ian Pavord et al. · New England Journal of Medicine · 2018 · 1.8K citations · Full text

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

, , +8

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Klaus F. Rabe, Parameswaran Nair, Guy Brusselle et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text

Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

Julia Gittler, Avner Shemer, Mayte Suárez‐Fariñas et al. · Journal of Allergy and Clinical Immunology · 2012 · 931 citations

, , +7